Phase II trial of vatalanib in patients with advanced or metastatic pancreatic adenocarcinoma after first-line gemcitabine therapy (PCRT O4-001) Academic Article uri icon

Overview

MeSH Major

  • Adenocarcinoma
  • Antineoplastic Combined Chemotherapy Protocols
  • Neoplasm Recurrence, Local
  • Pancreatic Neoplasms

abstract

  • Vatalanib was well tolerated as a second-line therapy and resulted in favorable 6-month survival rate in patients with metastatic pancreatic cancer, compared with historic controls.

publication date

  • January 2014

Research

keywords

  • Academic Article

Identity

Language

  • eng

PubMed Central ID

  • PMC4461053

Digital Object Identifier (DOI)

  • 10.1007/s00280-014-2499-4

PubMed ID

  • 24939212

Additional Document Info

start page

  • 379

end page

  • 87

volume

  • 74

number

  • 2